# CRC-AIM Public Repository

## Background

This is a public repository of information related to the Colorectal Cancer and Adenoma Incidence and Mortality (CRC-AIM) microsimulation model. CRC-AIM is a robust colorectal cancer (CRC) natural history and screening model that provides an accessible platform for collaborative simulation studies. This repository was created in the spirit of scientific engagement and transparency, and we will update it periodically as various components of CRC-AIM are added or improved.

## Collaborate

We are excited to collaborate with researchers and members of the modeling community to address outstanding questions related to colorectal cancer screening. If you are interested in working with us, please email us at collaborate@crcaim.com.

## Content

#### [v2.0](https://github.com/CRCAIM/CRC-AIM-Public/tree/master/v2.0): CRC-AIM v2.0
#### [v1.0](https://github.com/CRCAIM/CRC-AIM-Public/tree/master/v1.0): CRC-AIM v1.0 Archival Documents

## List of Publications & Abstracts

This is a comprehensive list of all the abstracts and publications that featured CRC-AIM, along with the corresponding versions of the model and parameters used.

### Publications
* [Kisiel JB, Fendrick AM, Ebner DW, et al. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening. J Med Econ. Published online April 30, 2024. doi:10.1080/13696998.2024.2349467](https://pubmed.ncbi.nlm.nih.gov/38686394/)

* [Ebner D, Kisiel J, Barnieh L, et al. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and Medicare population. J Med Econ. 2023;1-11. doi:10.1080/13696998.2023.2260681](https://pubmed.ncbi.nlm.nih.gov/37752872/)

* [Fendrick AM, Lieberman D, Chen JV, Vahdat V, Ozbay AB, Limburg PJ. Impact of eliminating cost-sharing by Medicare beneficiaries for follow-up colonoscopy after a positive stool-based colorectal cancer screening test. Cancer Res Commun. 2023;10.1158/2767-9764.CRC-23-0322. doi:10.1158/2767-9764.CRC-23-0322](https://pubmed.ncbi.nlm.nih.gov/37787758/)

* [Fendrick AM, Vahdat V, Chen JV, et al. Comparison of simulated outcomes between stool- and blood-based colorectal cancer screening tests. Popul Health Manag. 2023;26(4):239-245. doi:10.1089/pop.2023.0037](https://pubmed.ncbi.nlm.nih.gov/37466476/)

* [Vahdat V, Alagoz O, Chen JV, Saoud L, Borah BJ, Limburg PJ. Calibration and validation of the colorectal cancer and adenoma incidence and mortality (CRC-AIM) microsimulation model using deep neural networks. Med Decis Making. 2023;43(6):719-736. doi:10.1177/0272989X231184175.](https://pubmed.ncbi.nlm.nih.gov/37434445/)

* [Fendrick MA, Borah BJ, Burak Ozbay A, Saoud L, Limburg PJ. Life-years gained resulting from screening colonoscopy compared with follow-up colonoscopy after a positive stool-based colorectal screening test. Prev Med Rep. 2022;26:101701. Published 2022 Jan 19. doi:10.1016/j.pmedr.2022.101701](https://pubmed.ncbi.nlm.nih.gov/35106276/)

* [Fendrick AM, Fisher DA, Saoud L, Ozbay AB, Karlitz JJ, Limburg PJ. Impact of patient adherence to stool-based colorectal cancer screening and colonoscopy following a positive test on clinical outcomes. Cancer Prev Res (Phila). 2021;canprevres.0075.2021. doi:10.1158/1940-6207.CAPR-21-0075](https://pubmed.ncbi.nlm.nih.gov/34021023/)

* [Fisher DA, Karlitz JJ, Jeyakumar S, et al. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. J Med Econ. 2021;1. doi:10.1080/13696998.2021.1922240](https://pubmed.ncbi.nlm.nih.gov/33902366/)

* [Fisher DA, Saoud L, Finney Rutten LJ, Ozbay AB, Brooks D, Limburg PJ. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Curr Med Res Opin. Mar 26 2021:1. doi:10.1080/03007995.2021.1908244](https://pubmed.ncbi.nlm.nih.gov/33769894/)

* [Karlitz JJ, Fendrick AM, Bhatt J, et al. Cost-effectiveness of outreach strategies for stool-based colorectal cancer screening in a Medicaid population. Popul Health Manag. 2021;10.1089/pop.2021.0185. doi:10.1089/pop.2021.0185](https://pubmed.ncbi.nlm.nih.gov/34958279/)

* [Fisher DA, Saoud L, Hassmiller Lich K, et al. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model. Cancer Med. Dec 13 2020;doi:10.1002/cam4.3662](https://pubmed.ncbi.nlm.nih.gov/33314646/)

* [Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLoS One. 2020;15(12):e0244431. doi:10.1371/journal.pone.0244431](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771985)

* [Andrew Piscitello, Leila Saoud, Michael Matney, Bijan J Borah, A Mark Fendrick, Kristen Hassmiller Lich, Harald Rinde, Paul J Limburg: "Description and Validation of the Colorectal Cancer and Adenoma Incidence & Mortality (CRC-AIM) Microsimulation Model"  BioRxiv.org pre-print](https://www.biorxiv.org/content/10.1101/2020.03.02.966838v1) | NaturalHistory v1.0 & Screening v1.0

### Abstracts

* [Ebner DW, Kisiel J, Vahdat V, et al. S435 Cost-effectiveness of mt-sDNA vs fecal immunochemical test for colorectal cancer screening in a Medicare population. Am J Gastroenterol. 2023;118(10S):p S316. doi: 10.14309/01.ajg.0000951380.78109.e2](https://journals.lww.com/ajg/fulltext/2023/10001/s435_cost_effectiveness_of_mt_sdna_vs_fecal.791.aspx)

* [Vahdat V, Estes C, Ozbay B, et al. Impact of racial disparities in follow-up colonoscopy for abnormal stool-screening test results on colorectal cancer incidence and mortality: A simulation modeling analysis. 16th AACR Conference on the Sciences of Cancer Health Disparities and the Medically Underserved. October 29- November 2, 2023. Orlando, FL.](https://aacrjournals.org/cebp/article/32/12_Supplement/A138/730995/Abstract-A138-Impact-of-racial-disparities-in)

* [Ebner DW, Kisiel JB, Estes C, Vahdat V, Limburg P. The impact of extending CRC screening to the older population - results from CRC-AIM microsimulation model. Journal of Clinical Oncology. 2023; 41(16): S10567-10567. doi: 10.1200/JCO.2023.41.16_suppl.664210567.](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10567?af=R)

* [Fendrick AM, Kisiel JB, Ebner DW, et al. Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies. Journal of Clinical Oncology. 2023; 41(16): S10580-10580. doi: 10.1200/JCO.2023.41.16_suppl.10580.](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10580)

* [Kisiel JB, Fendrick AM, Borah BJ, et al. Estimated value-based pricing for Guardant Health Shield blood-based CRC screening test vs mt-sDNA test. American Society of Clinical Oncology Annual Meeting (ASCO) Annual Meeting. June 2-6, 2023. Chicago, IL.](https://meetings.asco.org/abstracts-presentations/223947)

* [Fendrick AM, Lieberman DA, Kisiel JB, et al. Colorectal cancer screening with blood-based tests: estimated impact of a 1-, 2-, or 3-year screening interval on benefits and harms compared with annual FIT and triennial mt-sDNA strategies. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.](https://eppro01.ativ.me/web/page.php?page=IntHtml&project=DDW23&id=3862125)

* [Kisiel JB, Lieberman DA, Fendrick AM, et al. Estimated adenoma sensitivity threshold needed for blood-based colorectal cancer screening tests to be as effective as stool-based screening tests. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.](https://eppro01.ativ.me/web/page.php?page=IntHtml&project=DDW23&id=3860879)

* [Kisiel JB, Fendrick AM, Borah B, et al. Estimated value-based pricing for Guardant Health Shield blood-based colorectal cancer screening test versus multi-target stool DNA test. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.](https://eppro01.ativ.me/web/page.php?page=IntHtml&project=DDW23&id=3862269)

* [Limburg P, Fendrick AM, Lieberman DA, et al. Cost-effectiveness of stool-based colorectal cancer screening programs from a health system perspective. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.](https://eppro01.ativ.me/web/page.php?page=IntHtml&project=DDW23&id=3863302)

* [Limburg P, Itzkowitz S, Lieberman DA et al. Estimated impact of adenoma and colorectal cancer early detection on health outcomes and screening effectiveness. Digestive Diseases Week. May 6-9, 2023. Chicago, IL.](https://eppro01.ativ.me/web/page.php?page=IntHtml&project=DDW23&id=3863355)

* [Fendrick AM, Chen JV, Ozbay AB, Vahdat V, Limburg PJ. S266 Lifetime impact of the change in modality as a result of eliminating cost-sharing for follow-up colonoscopy after a positive stool test for colorectal cancer screening. Am J Gastroenterol. 2022;117(10S)e189-e190. doi:10.14309/01.ajg.0000857704.03887.bd](https://journals.lww.com/ajg/Fulltext/2022/10002/S266_Lifetime_Impact_of_the_Change_in_Modality_as.266.aspx)

* [Fendrick MA, Vahdat V, Chen JV, et al. Comparison of simulated outcomes between stool-based and blood-based colorectal cancer screening tests. Journal of Clinical Oncology. 2022; 40(16): S10529. doi: 10.1200/JCO.2022.40.16_suppl.10529](https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.10529)

* [Fendrick AM, Piscitello A, Borah BJ, et al. Microsimulation study of life-years gained from screening versus follow-up colonoscopy using the CRC-AIM model. Digestive Disease Week 2020.](http://dx.doi.org/10.1016/S0016-5085(20)31623-1)

* [Limburg PJ, Saoud L, Borah BJ, et al. Higher impact on clinical outcomes from delays in colorectal cancer screening with the fecal immunochemical test vs multitarget stool DNA: CRC-AIM microsimulation model results. Digestive Disease Week 2020.](http://dx.doi.org/10.1016/S0016-5085(20)33610-6)

* [Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of imperfect adherence to stool-based colorectal cancer screening strategies on comparative effectiveness using the CRC-AIM microsimulation model. Digestive Disease Week 2020.](http://dx.doi.org/10.1016/S0016-5085(20)32962-0)

* [Piscitello A, Matney M, Saoud L, Parton M, Borah BJ, Limburg PJ, Rinde H. (2019) “PS 1-60: Validating a Novel Colorectal Cancer Natural History Microsimulation Model: The Colorectal Cancer and Adenoma Incidence Microsimulation Model (CRC-AIM).” SMDM Annual Meeting.](https://smdm.confex.com/smdm/2019/meetingapp.cgi/Paper/12716) | NaturalHistory v1.0
